BMY vs. ZTS, PFE, ABBV, MRK, JNJ, REGN, VRTX, GSK, SNY, and TAK
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), GSK (GSK), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical preparations" industry.
Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
In the previous week, Bristol-Myers Squibb had 53 more articles in the media than Zoetis. MarketBeat recorded 80 mentions for Bristol-Myers Squibb and 27 mentions for Zoetis. Bristol-Myers Squibb's average media sentiment score of 0.58 beat Zoetis' score of 0.13 indicating that Zoetis is being referred to more favorably in the media.
Zoetis has a net margin of 27.43% compared to Zoetis' net margin of -13.50%. Bristol-Myers Squibb's return on equity of 51.25% beat Zoetis' return on equity.
Zoetis has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Bristol-Myers Squibb received 183 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.76% of users gave Zoetis an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.1%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.4%. Zoetis pays out 34.1% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 12 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Zoetis currently has a consensus price target of $218.00, indicating a potential upside of 36.44%. Bristol-Myers Squibb has a consensus price target of $60.00, indicating a potential upside of 34.38%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than Bristol-Myers Squibb.
Summary
Zoetis beats Bristol-Myers Squibb on 15 of the 21 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Bristol-Myers Squibb Competitors List
Related Companies and Tools